Immunex Corporation

Omeros Corporation

University of Washington

Bristol-Myers Squibb Compnay

American Cyanamid Company

Wayne Richard Gombotz

Thomas Dudler

Anita Kavlie

Clark E Tedford

James Brian Parent

Sergej Kiprijanov

Richard L Remmele, Jr

Urs Beat Hagemann

Herald Reiersen

Dean K Pettit

Susan C Pankey

Gregory A Demopulos

Jeffrey M Herz

Suzie H Pun

Christopher Mount

Tae Hee Kim

Benjamin W Dulken

Allan Sachs Hoffman

William Christian Fanslow, Iii

James R Lawter

Hui-Rong Shen

Hui-rong Shen

SiowFong Wee

Russell J Mumper

Lisa S Bouchard

W James Huang

Siow Fong Wee

Richard L Remmele

Richard Remmele

The present invention relates to anti-MASP-2 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-2 dependent complement activation.

Compositions for inhibiting MASP-2 dependent complement activation

The present invention relates to an aqueous pharmaceutical composition suitable for long-term storage of polypeptides containing an Fc domain of an immunoglobulin, methods of manufacture, methods of administration and kits containing same.

Compositions comprising a P75 tumor necrosis factor receptor/Ig fusion protein

Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

Cyclooxygenase inhibitor and calcium channel antagonist compositions and methods for use in urological procedures

This disclosure is directed to mixed micelle compositions for administration of e.g., therapeutic agents or imaging agents to a subject.

Mixed micelles

The present invention relates to pharmaceutical compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein.

Compositions comprising a p75 tumor necrosis factor receptor/Ig fusion protein

Polypeptide formulation

Compositions of a cyclooxygenase inhibitor and a calcium channel antagonist in a liquid carrier. The composition may be administered the the urinary tract during urological diagnostic, interventional, surgical and other medical procedures. One disclosed composition comprises ketoprofen and nifedipine in a liquid irrigation carrier, and includes a solubilizing agent, stabilizing agents and a buffering agent.

Stable aqueous formulation of a soluble TNF receptor and arginine

Formulations for controlled, prolonged release of GM-CSF have been developed. These are based on solid microparticles formed of the combination of biodegradable, synthetic polymers such as poly(lactic acid) (PLA), poly(glycolic acid) (PGA), and copolymers thereof with excipients and drug loadings that yield zero order or first order release, or multiphasic release over a period of approximately three to twenty one days, preferably one week, when administered by injection. In the preferred embodiment, the microparticles are microspheres having diameters in the range of 10 to 60 microns, formed of a blend of PLGA having different molecular weights, most preferably 6,000, 30,000 and 41,000. Other embodiments have been developed to alter the release kinetics or the manner in which the drug is distributed in vivo. For example, in some cases a polymer is selected which elicits a mild inflammatory reaction, for example, PLGA and polyanhydrides can act as chemoattractant, either due to the polymer itself or minor contaminants in the polymer, or polymers which are bioadhesive are used for transmucosal or oral delivery. In another embodiment, the GM-CSF is administered in a hydrogel which can be injected subcutaneous or at a specific site for controlled release. The microparticles or hydrogel are administered to the patient in an amount effect to stimulate proliferation of hematopoietic cells, especially white cells.

Prolonged release of GM-CSF

Growing community of inventors

Kenmore, WA, United States of America

Wayne Richard Gombotz